Stockreport

Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF SNY seeks to offset looming Dupixent patent expirations by expanding into high-growth retinal therapeutics via OCUL's late-stage Axpaxli candidate. OCUL's valuation i [Read more]